Navigation Links
Bioheart, Inc. Announces Financial Results for First Quarter 2008
Date:5/15/2008

rt failure.

-- Bioheart initiated its patient registry clinical trial protocol for

MyoCell with MyoCath(R) Injection Catheter delivery in Korea, Singapore

and Switzerland, adding to the number of patients enrolled and

commitment to purchase Bioheart catheters for research purposes.

Other Business Highlights

-- On March 17, 2008, the Company was awarded a U.S. Patent for a method

to repair damaged myocardium (heart tissue) by a combination of cell

transplantation and electrostimulation. The award of this patent brings

to more than 100 the number of related patents and patents pending to

which the Company holds rights. The patent covers methods for repairing

damaged heart tissue by providing electrostimulation to patient-derived

myogenic cells either in the laboratory, while the cells are expanding,

or after the cells are implanted into the damaged areas of the

patient's heart.

-- The May 2008 issue of Cath Lab Digest featured an article on MyoCell

Therapy and the SEISMIC Trial and an interview with Warren Sherman, MD,

Director, Cardiac Cell-based Endovascular Therapies, Columbia

University Medical Center, New York, New York and Principal

Investigator of the MYOHEART Trial and the Phase II/III MARVEL Trial.

Revenues for the quarter ended March 31, 2008 increased to $25,995 compared to $13,805 in first quarter of 2007. During the quarter, we also recognized $61,500 of development revenue for services performed under a clinical registry agreement. The Company reported a net loss for the first quarter of 2008 of $3.3 million, or $(0.24) per share, compared to a net loss of $2.3 million, or $(0.18) per share, for the same quarter last year. The increase in the Company's net loss in the first quarter of 2008 as compared to the first quarter of 2007 is primarily attributable to increased interest expense r
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 OMICS Group’s 5th International ... 18-20 August, 2014 at Double Tree by Hilton Beijing, ... developments in Analytical & Bioanalytical research methods only to ... on this occasion, Dr. Srinubabu Gedela, MD of OMICS ... is a remarkable one in bringing a unique and ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
(Date:7/10/2014)... July 10, 2014 On July ... Medvedev , presented Russia,s first ... . The Company is developing a unique project called ... BIOCAD develops a number of innovative drugs based on ... The ceremony took place at the International Exhibition "Innoprom ...
(Date:7/10/2014)... 2014 /PRNewswire-iReach/ -- Tute Genomics, the leader ... an agreement with Lineagen, Inc., to provide ... Dx PLUS.  Lineagen, focused on the ... currently offers FirstStep Dx PLUS, a ... by healthcare providers as a first-line genetic ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... The long-awaited speaking faculty for the September Pharma ... the conference website reports Mark Alexay, President of ... is comprised of 100 speakers from pharmaceutical companies ... in the pipeline. The speaker list may be ...
... of Avastin Will Take Market Share Away from ... New Report from Decision ResourcesWALTHAM, Mass., March 10 ... research and advisory firms for pharmaceutical and healthcare ... in the age-related macular degeneration (AMD) market through ...
... March 10 Christine Lawless, MD, has ... an ACCME-accredited provider of continuing medical education (CME), beginning ... leading authorities in sports medicine cardiology, Dr. Lawless recently ... University Medical Center, where she was Associate Professor ...
Cached Biology Technology:Pharma ChemOutsourcing Unveils 100 Pharma & Biotech Speaker Faculty for 2009 Conference September 14-16 in Long Branch, NJ 2Robust Annual Growth Through 2012 in the Age-Related Macular Degeneration Market Will Be Driven by Expanding Use of Lucentis in Europe 2Robust Annual Growth Through 2012 in the Age-Related Macular Degeneration Market Will Be Driven by Expanding Use of Lucentis in Europe 3Former President of Sports Cardiology Consultants, LLC Christine Lawless, MD, MBA, ABCL, FACC, FACSM, Named Medical Director of CME Enterprise 2
(Date:7/11/2014)... TRAP" to capture the early signs of kidney failure, ... Journal of Clinical Investigation . Their new transgenic ... cellular and genetic information from a variety of solid ... for Medical Research in 2008, TRAP involves attaching a ... the cell type of interest. Scientists can then collect ...
(Date:7/11/2014)... China Researchers from Salk Institute for Biological Studies, ... evaluated the safety and reliability of the existing ... new method, TALEN-HDAdV, which could significantly increased gene-correction ... This study published online in Cell Stell ... stem cell-based gene therapy. , The combination of ...
(Date:7/11/2014)... explored two different ways that allow unprecedented experimental ... formation of oxygen molecules in photosynthesis. The two ... Nature Communications . , "The new knowledge ... water oxidation, which are key components for building ... solar energy in fuels like hydrogen, ethanol or ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Molecular snapshots of oxygen formation in photosynthesis 2
... to an Asian bark fungus accidentally introduced to the United ... was highly valued for its strong, workable lumber and a ... upon the chestnut for food. Ongoing efforts to reintroduce ... because they rely on genetic cross breeding to produce ...
... the United States have collaborated to complete the first ... called miscanthus. The results published in the current ... provide a significant breakthrough towards advancing the ... the long-term collaboration between energy crop company Ceres, Inc., ...
... line defence of the brain and are constantly looking ... uncontrolled inflammation within the brain, which can in turn ... Central,s open access journal Journal of Neuroinflammation ... production of pro-inflammatory cytokines and inflammatory enzymes in activated ...
Cached Biology News:UC research tests new tool to guide reintroduction of the American chestnut 2UC research tests new tool to guide reintroduction of the American chestnut 3First complete full genetic map of promising energy crop 2First complete full genetic map of promising energy crop 3The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage 2
IMAGEQUANT 100 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
Request Info...
RayBio Human Cytokine Antibody Array 1.1 (4 array membranes) with Accessory, detects 20 cytokines (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
...
Biology Products: